肝癌“双弹头”免疫导向药物的实验研究  

AN EXPERIMENTAL STUDY OF HEPATOCELLULAR CARCINOMA IMMUNOTARGETTING DRUG WITH “DUAL WARHEAD”

作　　者：隋延仿[1] 刘利[1] 陈志南[1] 刘彦仿[1] 王文亮[1] 

机构地区：[1]西安第四军医大学病理教研室

出　　处：《癌症》1994年第6期487-489,493,共4页Chinese Journal of Cancer

基　　金：国家自然科学基金

摘　　要：以肝细胞癌单克隆抗体ＨＡｂ１８为载体，应用间接交流方法及氯胺Ｔ法，将１３１Ｉ和抗癌药物阿霉素（ＡＤＭ）连接到ＨＡｂ１８上，制备出“双弹头”肝癌免疫导向药物１３１Ｉ─ＨＡｂ１８─ＡＤＭ，其标记率为８５％，比放射性为７．７３×ｌ０４Ｂｑ／μｇ（１．９８μＣｉ／μｇ），免疫结合率为４３．５％。细胞毒实验结果显示，１３１Ｉ─ＨＡｂ１８─ＡＤＭ对靶肿瘤细胞ＳＭＭＣ─７７２１的杀伤效果明显强于ＨＡｂ１８─ＡＤＭ、ＨＡｂ１８─１３１Ｉ、ＡＭＤ。１３１Ｉ─ＨＡｂ１８─ＡＤＭ具有选择性的高效杀伤作用，它集中了化疗与内放射治疗的优点，互相补充，展示了肿瘤导向治疗的光明前景。Using the monoclonal antibody of hepatocellular carcinoma HAb1 8 as cariers,131I-HAb18- Adriamycin (ADM) was prepared indirectly conjugated with dextran T-40 and chloramin-T method. The rate of its immunocombine power was 43.5%.131I-HAb18-ADM showed stronger selective in vitro cytotoxicity against the target tumor cells as compared with HAb18,131I-HAB18 conjugates etc. 131I─HAb18-ADM has both the advantage of chemotherapy and internal radiotherapy,it suggests that this congugate has a better effect for tumor targetting therapy.

关 键 词：肝细胞癌 单克隆抗体 阿霉素 碘131 导向疗法 

分 类 号：R735.705[医药卫生—肿瘤] R730.53[医药卫生—临床医学]